Form 8-K

8-K — Sintx Technologies, Inc.

Accession: 0001493152-26-045278

Filed: 2026-10-01

Period: 2026-10-01

CIK: 0001269026

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001269026

2026-10-01

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): October 1, 2026

SINTX

Technologies, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-33624

84-1375299

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

1885

West 2100 South

Salt

Lake City, UT 84119

(Address

of principal executive offices, including Zip Code)

Registrant’s

telephone number, including area code: (801) 839-3500

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class:

Trading

Symbol(s):

Name

of each exchange on which registered:

Common

Stock, par value $0.01 per share

SINT

The

NASDAQ Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

October 1, 2026, SINTX Technologies, Inc. (the “Company”) issued a press release announcing preliminary, unaudited revenue

for the fiscal quarter ended September 30, 2026 and providing an update regarding the Company’s previously announced revenue guidance.

The Company reported preliminary, unaudited revenue of approximately $2.2 million for the quarter ended September 30, 2026, of which

approximately $2.1 million was derived from product sales.

The

preliminary financial information described above is based on information currently available to management and remains subject to completion

of the Company’s quarter-end financial close and review procedures.

copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item

7.01. Regulation FD Disclosure.

described in the press release furnished as Exhibit 99.1, based on the preliminary quarterly revenue described under Item 2.02 above,

the Company intends to deliver a Call Notice to the holders of its outstanding Class B Common Stock Purchase Warrants (the “Class

B Warrants”) pursuant to the terms of the Class B Warrants.

The

Class B Warrants provide the Company with the right to call for exercise all or a portion of the outstanding Class B Warrants upon the

Company reporting Quarterly Revenue, as defined in the Class B Warrants, of at least $2.0 million for a fiscal quarter in a qualifying

Revenue Evidence Filing. The Company has determined that approximately $2.1 million of its revenue for the quarter ended September 30,

2026 constitutes Quarterly Revenue for purposes of the Class B Warrants.

The

press release also includes information regarding the Company’s fourth-quarter 2026 revenue outlook and certain business and operational

developments.

The

information furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed

“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or

otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing

under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

Exhibit

No.

Description

99.1

Press Release dated October 1, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

SINTX Technologies,

Inc.

Date:

October

1, 2026

By:

/s/

Eric K. Olson

Chief Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

SINTX

Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

Third-quarter

revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue

guidance

Revenue

milestone also enables Company to call Class B warrants

SALT

LAKE CITY, Utah – October 1, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”),

a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary,

unaudited revenue of $2.2 million* for the third quarter ended September 30, 2026. The result exceeds the high end of the Company’s

previously announced guidance of $0.9 million to $1.1 million, reflecting stronger-than-expected industrial ceramics sales, and is expected

to result in narrower losses than previous quarters.

Sales

of industrial parts to aerospace subsidiaries of Fortune 500 companies accounted for the majority of third-quarter revenue. During the

quarter, SINTX began shipments against the more than $3.2 million in contract manufacturing purchase orders announced in June,

converting a portion of those orders into recognized revenue. The Company reiterates its fourth-quarter revenue guidance range offered during its last quarterly earnings call.

“We

are pleased by the results of our efforts to improve manufacturing and operational efficiency in the third quarter,” said Eric

Olson, Chairman and CEO of SINTX. “In addition to the significantly narrowed losses we expect to see as a result of these sales

and nearly doubling the high end of the guidance we provided in August, our 2026 third-quarter revenue represents growth of roughly 380%

from the second quarter, and over ten times the revenue from the prior year quarter.”

During

2026, SINTX has expanded the commercial infrastructure supporting its silicon nitride orthopedic portfolio, including its FDA-cleared

SiNAPTIC® Foot & Ankle Osteotomy Wedge System. SINTX continues to develop its silicon nitride SiNERGY™ technology platform

across biocomposite and 3D printing capabilities, as well as its antimicrobial textiles as part of the overall platform for orthopedic,

spine, craniofacial, dental, suture and wound-management applications.

Mr.

Olson continued, “This quarter demonstrates our ability to turn industrial customer orders into revenue at scale through our U.S.

manufacturing operations. Our focus now is on reliable delivery, repeat business and disciplined manufacturing costs. We see this execution

as an important foundation for SINTX as we continue our transition towards a more diversified commercial-stage advanced materials company.”

Concurrent

with issuing this press release on Form 8-K, the Company also intends to deliver a Call Notice to the holders of Class B Warrants to

purchase an aggregate of approximately 1.88 million shares of the Company’s Common Stock. Roughly $2.1 million of the third-quarter

revenue was derived from product sales, surpassing the Call Right trigger of at least $2.0 million in product revenue during a fiscal

quarter. Per the terms of the Warrant, the per share exercise price shall be the closing price of the Company’s Common Stock at

the close of the trading day immediately preceding the date of the Call Notice; if fully exercised under the terms of the Warrant, cash

proceeds could provide up to $4.0 million in additional capital, while any Warrants or portion of Warrants that the Holders fail to exercise

in a timely manner will automatically expire. Exercise proceeds are not assured.

*This

amount represents preliminary recognized revenue for the quarter, while the Company is completing its quarter-end financial close and

review procedures. The preliminary revenue figure is based on information currently available to management, is unaudited, and remains

subject to adjustment. SINTX expects to provide complete third-quarter financial results in its forthcoming quarterly reporting. Final

reported revenue could differ materially.

About

SINTX Technologies, Inc.

Headquartered

in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures,

and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications.

SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic

industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract

manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SiNAPTIC® Foot

& Ankle Osteotomy Wedge System for reconstructive surgery.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking

statements include, among other things, statements regarding the Company’s expectations concerning its fourth-quarter 2026 revenue;

anticipated operating results, including expectations regarding narrowed losses; the Company’s ability to achieve reliable delivery,

repeat business and disciplined manufacturing costs; the continued development and commercialization of the Company’s silicon nitride

technology platform and related applications; the Company’s transition toward a more diversified commercial-stage advanced materials

company; the Company’s intention and ability to call the Class B Warrants; the potential exercise of such warrants by holders;

and the amount and availability of any proceeds resulting from such exercises. The Company’s reported third-quarter 2026 revenue

is preliminary and unaudited and remains subject to completion of the Company’s quarter-end financial close and review procedures.

Final reported results may differ from the preliminary results described in this release, including as a result of adjustments identified

during the closing and financial reporting process. Forward-looking statements are based on management’s current expectations,

estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those

expressed or implied by such statements. These risks and uncertainties include, among others, the Company’s ability to successfully

develop and commercialize its products and technologies; obtain and maintain applicable regulatory clearances or approvals; achieve market

acceptance among surgeons, healthcare providers, distributors and other customers; substantiate anticipated product characteristics and

performance; protect and enforce its intellectual property; manufacture products at commercial scale; satisfy customer orders on expected

schedules; maintain manufacturing throughput and operational efficiencies; manage manufacturing and operating costs; successfully execute

its strategic and commercial objectives; and the risks associated with the Class B Warrants, including that holders may not exercise

the warrants and that the Company may receive less proceeds than anticipated or no proceeds at all, as well as the risks and uncertainties

described in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors”

in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other SEC filings. Readers

are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. The Company

undertakes no obligation to update any forward-looking statement, except as required by applicable law.

Company

Contact:

Andrew

Benson

SINTX

Technologies, Inc.

801.839.3500

IR@sintx.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (6947 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 01, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 01, 2026

Entity File Number

001-33624

Entity Registrant Name

SINTX

Technologies, Inc.

Entity Central Index Key

0001269026

Entity Tax Identification Number

84-1375299

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1885

West 2100 South

Entity Address, City or Town

Salt

Lake City

Entity Address, State or Province

Entity Address, Postal Zip Code

84119

City Area Code

(801)

Local Phone Number

839-3500

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.01 per share

Trading Symbol

SINT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration